Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | GLI1 | P08151 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 5/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876323 | 0.83 | NOS2 (0.46) | NOS2NOS3NOS1GLI1PRCP | |
| SCHEMBL7871507 | 0.77 | NOS2 (0.41) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL7306276 | 0.75 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| Hydrochloric Acid SCHEMBL28244170 | 0.74 | NOS2 (0.38) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL8151169 | 0.73 | NOS2 (0.50) | NOS2NOS3NOS1GLI1DPP4 | |
| SCHEMBL6723813 | 0.72 | NOS2 (0.39) | NOS2NOS3NOS1GLI1PRCP | |
| SCHEMBL7331648 | 0.71 | NOS2 (0.36) | NOS2NOS3NOS1DPP4 | |
| SCHEMBL10686210 | 0.71 | NOS2 (0.36) | NOS2NOS3NOS1DPP4HTR2C | |
| Hydrochloric Acid SCHEMBL8976071 | 0.71 | NOS2 (0.36) | NOS2NOS3NOS1DPP4 | |
| SCHEMBL8197551 | 0.71 | NOS2 (0.34) | NOS2NOS3NOS1PRCPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389360-A2 | A PROCESS FOR THE PREPARATION OF ZOFENOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Glenmark Generics Limited (IN) | 2011-11-30 | — | — | EP | disclosed |
| US-20110281928-A1 | Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof | GLENMARK GENERICS LTD (IN) | 2011-11-17 | — | — | US | disclosed |
| US-20110253651-A1 | Drying rack with wrap-around cover | BEHJAT MOHAMMAD KAZEM | 2011-10-20 | — | — | US | disclosed |
| WO-2010084515-A2 | A PROCESS FOR THE PREPARATION OF ZOFENOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLENMARK GENERICS LIMITED (IN) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281928-A1 | Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof | ACE, REN, PEPD | NOS2 1267/4885NOS3 935/4885NOS1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.